July 20, 2016
The Treatment of Obesity – FDA Approves BELVIQ XR ER
Share this post
On July 19, Eisai, Inc., and Arena Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) approved BELVIQ XR (lorcaserin HCl) CIV extended-release 20 mg tablets for the treatment of obesity. Previously the FDA approved a 10 mg, twice-daily tablet for obesity treatment use with a reduced-calorie diet and increased physical activity for adults with obesity. The new formulation approved today will offer patients a once-a-day option for obesity treatment, weight loss, and weight maintenance.